Nonclinical Development Science Services Blog Post
Download PDF
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions Blog Post
March 5, 2025 McKemey joins Certara to accelerate growth of its strategic drug development solutions RADNOR, PA – March 5th, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in... Certara Integral: The Master Data Repository Powering Efficient and Collaborative PK/PD Workflows Blog Post
April 15, 2025 – 11am ET
Behind the Science: A Conversation with Katrina Hui Blog Post
You May Also Like AllVideo Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at CertaraBlending Science & Impact in Drug Development: Felix Boakye-Agyeman,...
Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach Blog Post
Overview This study explores a model-based meta-analysis (MBMA) and a clinical utility index (CUI) approach to assess the benefit–risk profiles of antibody–drug conjugates (ADCs). The focus is on two approved...
Machine Learning for PK/PD Modeling in Drug Development Blog Post
Pharmacometricians can use machine learning for PK/PD modeling to help them characterize the safety and efficacy of investigational drugs more efficiently.
